What are the symptoms of bone metastasis from prostate cancer?

Written by Zhou Zi Hua

Oncology

Updated on September 09, 2024

00:00

00:00

Bone metastasis is the most common site of metastasis for prostate cancer, with the lumbar vertebrae being the most common site. Eighty percent of bone metastases in prostate cancer are osteoblastic changes. The main symptoms caused by bone metastasis are bone pain, pathological fractures, anemia, and if the spinal cord is compressed, it can cause paralysis of the lower limbs, weakness, incontinence, and other symptoms.

Other Voices

home-news-image

Written by Liu Liang

Oncology

1min

home-news-image

How long can one survive with prostate cancer?

The life expectancy of prostate cancer patients depends on the clinical stage at diagnosis, as well as the patient's sensitivity to various treatments such as endocrine therapy, chemotherapy, and radiotherapy. Patients diagnosed at earlier stages who are more responsive to treatment generally have better treatment outcomes and, consequently, a longer survival period compared to those who are diagnosed at later stages and have poor responses to treatment. Overall, prostate cancer patients tend to have a relatively long disease course, and the prognosis is generally good. Even patients with advanced prostate cancer exhibiting extensive bone metastasis can survive several years due to the effectiveness of endocrine treatments. The disease itself progresses slowly, so the prognosis for this type of cancer is comparatively favorable.

home-news-image

Written by Zhou Zi Hua

Oncology

34sec

home-news-image

How to treat bone metastases from prostate cancer?

The treatment of bone metastases from prostate cancer can include first-line hormonal therapy. During hormonal treatment, bisphosphonates can be used in conjunction to increase bone density. Additionally, external radiation therapy can improve localized bone pain. Patients with multiple bone metastases or bone pain can undergo radionuclide therapy. Another method is the use of analgesic drug therapy, which is also a main approach to alleviate pain from bone metastases of prostate cancer.

home-news-image

Written by Liu Liang

Oncology

43sec

home-news-image

Is prostate cancer prone to metastasis?

Prostate cancer most commonly metastasizes to bones, with multiple bone metastases frequently observed clinically. In fact, the majority of prostate cancer patients already have multiple bone metastases by the time they are diagnosed. Therefore, bone is the most common distant organ to which prostate cancer spreads. Other distant organ metastases, such as to the lungs and liver, are less common, unless in very advanced stages of the disease. Additionally, prostate cancer commonly invades locally, spreading to nearby pelvic structures and tissues, such as the bladder and rectum, which is a common form of local invasion and spread.

home-news-image

Written by Zhou Zi Hua

Oncology

40sec

home-news-image

Prostate Cancer Treatment Options

How is prostate cancer treated? The choice of treatment plan should be based on a comprehensive consideration of the patient's clinical stage, age, overall health, and expected lifespan. For example, in the early stages of prostate cancer, one can choose postoperative radical radiotherapy after prostatectomy. For locally advanced prostate cancer, radiotherapy, intensified radiotherapy combined with endocrine therapy can be chosen. For metastatic prostate cancer, endocrine therapy is mainly used, and chemotherapy can be adopted for those who are ineffective or fail endocrine therapy.

home-news-image

Written by Zhou Zi Hua

Oncology

40sec

home-news-image

androgen deprivation therapy for prostate cancer

Androgen deprivation therapy for prostate cancer includes surgical castration, which can quickly and continuously reduce levels to very low levels. The second is medical castration, which involves the use of analogs of luteinizing hormone-releasing hormone. Currently available products include leuprolide, goserelin, and triptorelin. Third, estrogen therapy, with diethylstilbestrol being the most common estrogen treatment. Surgical castration, medical castration, or estrogen therapy offer similar progression-free survival rates in patients with tumor-related outcomes.